BIIB Biogen (BIIB) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000875045
Congress · 2Form 144 · 2
Insider buyers, 180 days
0
Funds added, last quarter
556
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $0 priced
What the filings say about BIIB
Insiders, 180 days
-$239.7K net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
2 bought · 2 sold
Latest: sale, 2026-09-24
Planned sales (Form 144), 90 days
$239.7K
2 notices
Biogen insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BIOGEN INC. insiders sold a net $239.7K of stock across 26 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 3, 2026.
- The trade is 22.1% of the 2,689 shares held after it.
- No other insider sold within 30 days.
- 556 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Minor Lloyd sold about $119.2K of BIIB on Aug 4, 2026; 556 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 18.1% of the 3,282 shares held after it.
- No other insider sold within 30 days.
- 556 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Minor Lloyd sold about $120.6K of BIIB on Aug 3, 2026; 556 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.0% of the 19,611 shares held after it.
- No other insider bought within 30 days.
- 556 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Head of Pharm Ops and Tech Murphy Nicole bought about $585 of BIIB on Feb 12, 2026; 556 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Feb 2, 2026.
- The trade is 33.1% of the 8,043 shares held after it.
- No other insider sold within 30 days.
- 556 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Head of Development Singhal Priya sold about $531.5K of BIIB on Feb 9, 2026; 556 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Sep 2, 2025.
- The trade is 11.9% of the 6,271 shares held after it.
- No other insider sold within 30 days.
- 556 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Head of Development Singhal Priya sold about $134.1K of BIIB on Feb 2, 2026; 556 funds added in the latest 13F quarter.26 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$239.7K over 180 days
-$239.7K over 90 days
more than 51% of Pharma & Biotech
Congress
2 members bought in the last year
more than 76% of Pharma & Biotech
Funds
556 funds bought in last quarter
more than 98% of Pharma & Biotech
Revenue
+2.2% year over year
below 51% of Pharma & Biotech
Margin
13.1% net margin
more than 83% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
3.7% of the float short (float per yahoo 2026-10-27) · 4.4 days to cover · settled 2026-10-15
below 55% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 7Rep. Maria Elvira Salazar sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch BIIB
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+68.4%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BIIB: institutional holders (13F)
13F holdings, latest reported quarter
18,217,239 sh
$3.9B
15,985,736 sh
$3.5B
15,154,606 sh
$3.3B
9,651,117 sh
$2.1B
7,344,327 sh
$1.6B
Congress trades in BIIB
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-24 · disclosed 13 days later
$1,001 - $15,000
Sold 2026-08-18 · disclosed 14 days later
$1,001 - $15,000
Bought 2026-06-05 · disclosed 27 days later
$1,001 - $15,000
Sold 2026-06-02 · disclosed 35 days later
$15,001 - $50,000
Bought 2026-05-12 · disclosed 27 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BIIB planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Minor Lloyd
Filed 2026-08-04
$119.2K
Minor Lloyd
Filed 2026-08-03
$120.6K
BIIB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Biotechnology & Genome ETF
$13.5M position · as of 2026-07-31
4.8%
First Trust Nasdaq Pharmaceuticals ETF
$1.4M position · as of 2026-06-30
3.8%
VanEck Biotech ETF
$14.3M position · as of 2026-06-30
3.6%
iShares Health Innovation Active ETF
$392.7K position · as of 2026-07-31
3.5%
First Trust NYSE Arca Biotechnology Index Fund
$94.8M position · as of 2026-06-30
3.4%
Hennessy Sustainable ETF
$2.9M position · as of 2026-07-31
3.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
200 registered trials, 42 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
59
Phase 1
6 active
35
Phase 2
4 active
47
Phase 3
16 active
7
Phase 4
1 active
45
Not applicable
13 active
7
Multi-phase
2 active
What changed recently
A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic
2026-10-20 · Not Yet Recruiting → Recruiting
PHASE1,PHASE2
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141)
2026-10-03 · Recruiting → Active Not Recruiting
Phase 3
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in
2026-10-01 · Completion moved 2031-05-28 → 2031-12-31
Phase 3
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and
2026-09-23 · Completion moved 2030-03-29 → 2032-05-03
Phase 3
A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Par
2026-09-09 · Recruiting → Completed
,
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn Mo
2026-09-04 · Completion moved 2025-09-30 → 2030-06-04
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Biogen Inc. Political Action Committee A.K.A 'Biogen Pac'
Cycle 2026 · $125K spent
$102.0K
Federal Election Commission, matched by the PAC's connected organisation
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $239.7K sold by insiders over 180 days, 556 funds added last quarter, 2 House member(s) bought in 12 months, disclosed weeks after the trade, $239.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
BIIB financials
Revenue growth
+2.2%
XBRL, annual
Net margin
13.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$9.9B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM BIIB
| FY Dec 2025 | $9.9B |
| FY Dec 2024 | $9.7B |
| FY Dec 2023 | $9.8B |
| FY Dec 2022 | $10.2B |
| FY Dec 2021 | $11.0B |
| Mar 2026 | $2.5B |
| Dec 2025 | $2.3B |
| Sep 2025 | $2.5B |
| Jun 2025 | $2.6B |
| Mar 2025 | $2.4B |
| Dec 2024 | $2.5B |
| Sep 2024 | $2.5B |
| Jun 2024 | $2.5B |
At each fiscal year end
Single quarter
Net margin, TTM
+13.8%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM BIIB
| FY Dec 2025 | +13.1% |
| FY Dec 2024 | +16.9% |
| FY Dec 2023 | +11.8% |
| FY Dec 2022 | +30.0% |
| FY Dec 2021 | +14.2% |
| Mar 2026 | +12.9% |
| Dec 2025 | -2.1% |
| Sep 2025 | +18.4% |
| Jun 2025 | +24.0% |
| Mar 2025 | +9.9% |
| Dec 2024 | +10.9% |
| Sep 2024 | +15.8% |
| Jun 2024 | +23.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$2.4B
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM BIIB
| FY Dec 2025 | $2.1B |
| FY Dec 2024 | $2.7B |
| FY Dec 2023 | $1.3B |
| FY Dec 2022 | $1.1B |
| FY Dec 2021 | $3.4B |
| Mar 2026 | $594.3M |
| Dec 2025 | $468.0M |
| Sep 2025 | $1.2B |
| Jun 2025 | $134.3M |
| Mar 2025 | $222.2M |
| Dec 2024 | $721.6M |
| Sep 2024 | $900.6M |
| Jun 2024 | $592.3M |
At each fiscal year end
Single quarter
Debt to equity
0.34x
long-term 2026-03-31 plus current 2025-12-31; equity 2026-03-31
Debt to equity BIIB
| FY Dec 2025 | 0.34x |
| FY Dec 2024 | 0.38x |
| FY Dec 2023 | 0.47x |
| FY Dec 2022 | 0.47x |
| FY Dec 2021 | 0.67x |
| Mar 2026 | 0.34x |
| Dec 2025 | 0.34x |
| Sep 2025 | 0.44x |
| Jun 2025 | 0.46x |
| Mar 2025 | 0.37x |
| Dec 2024 | 0.38x |
| Sep 2024 | 0.29x |
| Jun 2024 | 0.41x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.41x
TTM operating cash flow over long-term 2026-03-31 plus current 2025-12-31
Cash flow to debt BIIB
| FY Dec 2025 | 0.35x |
| FY Dec 2024 | 0.46x |
| FY Dec 2023 | 0.22x |
| FY Dec 2022 | 0.22x |
| FY Dec 2021 | 0.50x |
| Mar 2026 | 0.41x |
| Dec 2025 | 0.35x |
| Sep 2025 | 0.31x |
| Jun 2025 | 0.26x |
| Mar 2025 | 0.41x |
| Dec 2024 | 0.46x |
| Sep 2024 | 0.45x |
| Jun 2024 | 0.28x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+7.7%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity BIIB
| FY Dec 2025 | +7.4% |
| FY Dec 2024 | +10.4% |
| FY Dec 2023 | +8.2% |
| FY Dec 2022 | +25.1% |
| FY Dec 2021 | +14.4% |
| Mar 2026 | +7.7% |
| Dec 2025 | +7.4% |
| Sep 2025 | +9.3% |
| Jun 2025 | +9.1% |
| Mar 2025 | +9.2% |
| Dec 2024 | +10.4% |
| Sep 2024 | +10.5% |
| Jun 2024 | +7.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.8%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets BIIB
| FY Dec 2025 | +4.5% |
| FY Dec 2024 | +5.9% |
| FY Dec 2023 | +4.5% |
| FY Dec 2022 | +12.6% |
| FY Dec 2021 | +6.4% |
| Mar 2026 | +4.8% |
| Dec 2025 | +4.5% |
| Sep 2025 | +5.6% |
| Jun 2025 | +5.6% |
| Mar 2025 | +5.4% |
| Dec 2024 | +5.9% |
| Sep 2024 | +5.7% |
| Jun 2024 | +4.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+9.5%
operating income after a 15.5% effective tax rate, over long-term 2026-03-31 plus current 2025-12-31 plus average of 2025-03-31 and 2026-03-31 minus cash
Return on invested capital BIIB
| FY Dec 2025 | +9.5% |
| FY Dec 2024 | +10.6% |
| FY Dec 2023 | +11.7% |
| FY Dec 2022 | +12.5% |
| FY Dec 2021 | +17.2% |
| Mar 2026 | +9.5% |
| Dec 2025 | +9.5% |
| Sep 2025 | +9.0% |
| Jun 2025 | +9.3% |
| Mar 2025 | +10.3% |
| Dec 2024 | +10.6% |
| Sep 2024 | +11.6% |
| Jun 2024 | +11.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+10.1%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed BIIB
| FY Dec 2025 | +10.2% |
| FY Dec 2024 | +10.8% |
| FY Dec 2023 | +11.1% |
| FY Dec 2022 | +12.1% |
| FY Dec 2021 | +14.0% |
| Mar 2026 | +10.1% |
| Dec 2025 | +10.2% |
| Sep 2025 | +10.2% |
| Jun 2025 | +10.1% |
| Mar 2025 | +10.8% |
| Dec 2024 | +10.8% |
| Sep 2024 | +10.8% |
| Jun 2024 | +10.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
27.18x
close 2026-10-27 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing BIIB
| FY Dec 2025 | 20.02x |
| FY Dec 2024 | 13.67x |
| FY Dec 2023 | 32.43x |
| FY Dec 2022 | 13.22x |
| FY Dec 2021 | 23.07x |
| Mar 2026 | 19.71x |
| Dec 2025 | 20.02x |
| Sep 2025 | 12.77x |
| Jun 2025 | 12.01x |
| Mar 2025 | 13.51x |
| Dec 2024 | 13.67x |
| Sep 2024 | 17.51x |
| Jun 2024 | 29.20x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$40.7B
market value at close 2026-10-27 on 2026-04-27 shares, plus long-term 2026-03-31 plus current 2025-12-31, minus cash 2019-12-31
Enterprise value BIIB
| FY Dec 2025 | $29.2B |
| FY Dec 2024 | $25.7B |
| FY Dec 2023 | $41.5B |
| FY Dec 2022 | $43.2B |
| FY Dec 2021 | $39.6B |
| Mar 2026 | $30.3B |
| Dec 2025 | $29.2B |
| Sep 2025 | $25.7B |
| Jun 2025 | $23.5B |
| Mar 2025 | $23.4B |
| Dec 2024 | $25.7B |
| Sep 2024 | $30.0B |
| Jun 2024 | $37.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.5%
TTM free cash flow over market value at close 2026-10-27
FCF yield BIIB
| FY Dec 2025 | +7.9% |
| FY Dec 2024 | +12.2% |
| FY Dec 2023 | +3.4% |
| FY Dec 2022 | +2.9% |
| FY Dec 2021 | +9.6% |
| Mar 2026 | +9.0% |
| Dec 2025 | +7.9% |
| Sep 2025 | +11.2% |
| Jun 2025 | +10.8% |
| Mar 2025 | +12.2% |
| Dec 2024 | +12.2% |
| Sep 2024 | +6.9% |
| Jun 2024 | +4.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -8%, PEG needs growth
PEG, trailing BIIB
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.34x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.13x |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 0.38x |
| Mar 2025 | 0.51x |
| Dec 2024 | 0.34x |
| Sep 2024 | 1.76x |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $9.9B | $9.7B | $9.8B | $10.2B |
| Net income | $1.3B | $1.6B | $1.2B | $3.0B |
| EPS (diluted) | 8.79 | 11.18 | 7.97 | 20.87 |
| Operating cash flow | $2.2B | $2.9B | $1.5B | $1.4B |
| Long-term debt | $6.3B | $4.5B | $6.8B | $6.3B |
| Buybacks | n/a | $0 | $0 | $750.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
BIIB Stock Sonar score 6/7 axes
Find similar shapesCompareBIIB ranks highest on institutional and government (75th percentile) and profitability (74th), and lowest on insider conviction (24th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BIIB filings, in plain words
Are Biogen insiders buying or selling BIIB?
In the 180 days to 2026-10-28, Biogen insiders were net sellers, a net $239.7K across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded BIIB?
Yes. In the year to 2026-10-28, 2 House members disclosed buying BIIB and 2 House members disclosed selling it; the latest on record is a sale by Maria Elvira Salazar dated 2026-09-24.
Are there planned insider sales of BIIB?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $239.7K of stock; the latest, by Minor Lloyd, was filed 2026-08-04.
Read the full summary
In the 180 days to 2026-10-28, Biogen insiders were net sellers of BIIB, a net $239.7K across purchases and sales reported on Form 4 by 1 seller. In the year to 2026-10-28, 2 members of Congress disclosed buying BIIB and 2 members disclosed selling it; the latest on record is a sale by Maria Elvira Salazar dated 2026-09-24. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $239.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
